Clinical Trial Update: Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2 [EARLY_Phase 1]

View source ↗

Summary

This EARLY_PHASE1 clinical trial from Shanghai General Hospital evaluates a combination of donor-derived regulatory T cell injections and recombinant human inte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Donor-derived regulatory T cell injection (regulatory T cells)
• Recombinant human interleukin-2 (interleukin-2)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: cGVHD | EARLY_Phase 1 | Status: RECRUITING